As the calendar flips and the industry collectively resolves to innovate smarter, faster, and with fewer regulatory headaches, FDA has offered an early New Year’s surprise. The Center for Devices and Radiological Health (CDRH) has issued an updated version of its General Wellness: Policy for Low Risk Devices guidance—an update that meaningfully reshapes the regulatory landscape for wellness technologies and wearables.
While FDA did not revise the formal definition of a “general wellness product,” it significantly expanded the types of products that can fall within that category. The practical effect is notable: many more products may now reach the market without FDA premarket review. Just as notably, the revised guidance quietly—but decisively—walks back the reasoning underpinning FDA’s prior Warning Letter to WHOOP, signaling a broader recalibration of the agency’s approach to physiological monitoring for non-medical purposes.
By way of reminder, in the WHOOP Warning Letter FDA asserted that the company’s blood pressure feature could not qualify as a general wellness product, reasoning that blood pressure measurement is “inherently associated” with the diagnosis of hypertension and hypotension. That concept—claims being disqualifying simply by virtue of their association with disease—raised eyebrows at the time, as it appeared untethered from FDA’s longstanding intended-use framework.
The revised General Wellness Guidance represents a clear pivot. FDA now states that it may consider products that use non-invasive sensing technologies—such as optical sensors—to estimate or infer physiological parameters (including blood pressure, oxygen saturation, blood glucose, and heart rate variability) to be general wellness products, provided that the outputs are intended solely for wellness uses and the products meet a defined set of criteria. These include being non-invasive, posing no undue safety risks, avoiding disease-related claims, not substituting for FDA-authorized devices, and steering clear of functionality that prompts clinical action or medical management. Importantly, the guidance emphasizes that such products must not present themselves as clinically accurate unless appropriately validated.
In short, FDA has moved from suggesting that certain measurements are categorically medical to acknowledging that context, labeling, and intended use matter—and matter a great deal. Measurement alone, without more, is no longer enough to transform a product into a regulated medical device.
This shift provides welcome clarity in an area that has long felt uneven. Major technology companies have for years offered heart rate and other physiological monitoring features in consumer wearables, sometimes including alerts when values fall above or below certain levels. The regulatory basis for concluding that these features were not medical devices was often opaque, particularly to smaller or more risk-averse companies that sought FDA input on similar products and were told they crossed the line simply by measuring physiological parameters. The updated guidance suggests that such conclusions are increasingly difficult to square with FDA’s current thinking.
That said, the guidance is not without its ambiguities. One area of potential confusion lies in FDA’s discussion of ranges and thresholds. The guidance states that general wellness products may not include values that “mimic those used clinically” unless validated, yet elsewhere indicates that diagnostic thresholds should not be included at all. Instead, manufacturers are encouraged to rely on “ranges appropriate for general wellness use,” a concept that is both novel and underexplained. How such ranges are to be established—and whether they will be consistent across products—remains unclear, particularly given other language suggesting that validated clinical values may, in some circumstances, be acceptable.
Similarly, while FDA clarifies that general wellness products may advise users to seek evaluation by a healthcare professional, it cautions against doing so on the basis that an output is “abnormal.” Advising consumers to seek medical input without explaining the reason may reduce regulatory risk, but it may also introduce real-world confusion.
Overall, the revised General Wellness Guidance reflects a broader policy direction favoring deregulation and the expansion of consumer-facing health technologies. The update addresses longstanding concerns that FDA’s oversight of low-risk software and wellness products was, at times, overly conservative. At the same time, it raises important questions about how FDA will balance innovation with patient safety—particularly as products increasingly provide users with data that, while labeled “wellness,” may still influence health-related decisions.
For industry, the takeaway is cautiously optimistic. FDA has opened the door wider for wellness innovation, but companies must still tread carefully. Intended use, labeling discipline, and thoughtful validation remain critical. In this New Year, FDA may be signaling flexibility—but it is not abandoning the expectation that manufacturers know precisely what they are claiming, and just as importantly, what they are not.
For more information on FDA’s general wellness policy or for other questions on FDA medical device compliance and enforcement issues, please email info@garg-law.com.
